Stock Research: Dr. Reddy's

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Dr. Reddy's

BSE:500124 INE089A01023
87
  • Value
    49
  • Growth
    95
  • Safety
    Safety
    69
  • Combined
    96
  • Sentiment
    50
  • 360° View
    360° View
    87
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. It operates in the pharmaceutical industry, specializing in APIs, generics, branded generics, biosimilars, and OTC pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. In the last fiscal year, the company had a market cap of $12,191 million, profits of $2,558 million, and revenue of $3,820 million, with 26944 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 87 (better than 87% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Dr. Reddy's are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Dr. Reddy's. The consolidated Value Rank has an attractive rank of 69, which means that the share price of Dr. Reddy's is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 69% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 95, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 50. But the company’s financing is risky with a Safety rank of 49. This means 51% of comparable companies have a safer financing structure than Dr. Reddy's. ...read more

more
Index
Good Governace Growth Markets
Independent Boards Growth Markets
Low Waste
Recycling
CNX Nifty 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
69 65 63 61
Growth
95 13 31 47
Safety
Safety
49 51 59 47
Sentiment
50 43 84 50
360° View
360° View
87 25 76 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
17 21 38 83
Opinions Change
34 10 39 50
Pro Holdings
n/a 54 99 8
Market Pulse
79 88 77 57
Sentiment
50 43 84 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
69 65 63 61
Growth
95 13 31 47
Safety Safety
49 51 59 47
Combined
96 21 53 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
75 75 82 63
Price vs. Earnings (P/E)
60 56 62 61
Price vs. Book (P/B)
63 57 62 58
Dividend Yield
39 42 37 42
Value
69 65 63 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
91 48 17 46
Profit Growth
39 25 51 86
Capital Growth
98 1 46 42
Stock Returns
65 43 67 21
Growth
95 13 31 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
45 56 60 44
Refinancing
68 72 74 66
Liquidity
41 46 52 47
Safety Safety
49 51 59 47

Similar Stocks

Discover high‑ranked alternatives to Dr. Reddy's and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

REC

NSEI:RECLTD
Country: India
Industry: Specialized Finance
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.